Portfolio news Archives - Page 8 of 13

BaseLaunch and WuXi Biologics announce their partnership

We are pleased to announce the partnership between BaseLaunch and WuXi Biologics! WuXi Biologics is a global Contract Research, Development and Manufacturing Organization with operations…

Martyna Wroblewska26.09.2022

Portfolio news

Phialogics joins BaseLaunch Portfolio

We are excited to welcome Phialogics as our newest portfolio company! Basel, Switzerland. 20 September 2022 - Phialogics is a preclinical stage company developing cell-type-specific…

Martyna Wroblewska20.09.2022

Portfolio news

Roivant’s growth story

Want to know how to grow a global biopharma company from scratch into a leader in their field? Read about the key insights from our…

Martyna Wroblewska19.09.2022

Portfolio news

BaseLaunch and Schrödinger announce their partnership

We are pleased to announce the partnership between BaseLaunch and Schrödinger! A pioneer in pharmaceutical software, Schrödinger was founded in 1990. The company’s mission to…

Martyna Wroblewska16.09.2022

Portfolio news

BaseLaunch’s Mission: Building Exceptional Biotech Companies

Many factors must come together to see a biotech venture succeed. Unique ideas and exceptional science discoveries are important criteria, as are risk-taking and entrepreneurial…

Martyna Wroblewska25.08.2022

Portfolio news

Charles River announces partnership with BaseLaunch

Charles River Laboratories and BaseLaunch have announced their partnership! With 120 sites around the globe, Charles Rivers is strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving their…

Arianna26.07.2022

Portfolio news

InCephalo AG Announces Appointment of Lauren E. Abrey, MD as Chief Medical Officer

InCephalo AG announces that Lauren E. Abrey, MD will join the company as Chief Medical Officer (CMO). Dr. Abrey will lead the clinical and medical…

Arianna30.06.2022

Portfolio news

How Lonza’s Ibex® Design 2.0 Program Accelerates Time to IND

From DNA to TOX drug substance in 5 months and IND in 11 months. Speed to clinic and to market is increasingly gaining importance among…

Arianna30.06.2022

Portfolio news

Wuxi AppTec partnership with BaseLaunch renewal

In an effort to further grow the flow of innovation centered in the Basel Area, WuXi AppTec and BaseLaunch have renewed their partnership to join forces to help young biopharmaceutical enterprises overcome some of…

Arianna30.06.2022

Portfolio news

Accessing TCR Discovery Capabilities with Alloy Therapeutics

In particular, TCR-based therapeutics hold great promise to improve immunotherapies, as T cells are key players in adaptive immune response leading to curative effects in…

Arianna30.06.2022

Portfolio news

BaseLaunch and WuXi Biologics announce their partnership

Phialogics joins BaseLaunch Portfolio

Roivant’s growth story

BaseLaunch and Schrödinger announce their partnership

BaseLaunch’s Mission: Building Exceptional Biotech Companies

Charles River announces partnership with BaseLaunch

InCephalo AG Announces Appointment of Lauren E. Abrey, MD as Chief Medical Officer

How Lonza’s Ibex® Design 2.0 Program Accelerates Time to IND

Wuxi AppTec partnership with BaseLaunch renewal

Accessing TCR Discovery Capabilities with Alloy Therapeutics

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us